Building Successful Programs for Hypertension Patients
High blood pressure is a leading risk factor for heart disease and stroke, affecting nearly half of US adults and contributing to 685,875 deaths in 2022, according to the Centers for Disease Control and Prevention.
Although the FDA approved two renal denervation (RDN) systems for the treatment of hypertension in 2023, reimbursement was limited, restricting access to treatment for many patients.
In January 2025, this changed when Medicare approved Transitional Pass-Through (TPT) reimbursement for Medtronic and Recor Medical RDN systems.
Expanded patient eligibility offers hope of increasing healthcare system integration and adoption of the procedure, driving more consistent and widespread use of RDN as a treatment option—great news for practitioners wanting to establish new therapeutic programs and the large numbers of patients not responding to traditional hypertension treatments who could benefit.
Designed for Interventional Cardiologists, HTN Experts, Hypertension Clinical Coordinators, and Others Involved in Building Your RDN Program
This new course from SCAI:
- Focuses on the nuts and bolts of building a thriving RDN center at your institution.
- Assesses the potential clinical and practice implications for renal denervation treatment.
- Delves into patient selection including pre- and post-procedural considerations.
- Reviews expert guidance on best practices and treatment selection for these complex cases.
- Explores ways to improve collaboration among specialists, enhance the quality of care, and optimize outcomes for hypertensive patients requiring advanced therapies like RDN.
Featuring Case-Based Discussions and Hands-On Learning Labs
Attendees leave equipped with the knowledge they need to evaluate their programs to ensure they align with real-world contemporary RDN practice.
Follow #SCAIRDN for the Latest Updates